Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 6/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | ALDH1A3 | P47895 | 12/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3430509 | 0.82 | NR4A2 (0.61) | NR4A2KCNH2CYP11B1CYP11B2ALDH1A3 | |
| SCHEMBL3432224 | 0.80 | NR4A2 (0.61) | NR4A2KCNH2CYP11B1CYP11B2ALDH1A3 | |
| SCHEMBL3431381 | 0.80 | NR4A2 (0.64) | NR4A2KCNH2CYP11B1CYP11B2ALDH1A3 | |
| SCHEMBL3433850 | 0.79 | NR4A2 (0.66) | NR4A2KCNH2CYP11B1CYP11B2ALDH1A3 | |
| SCHEMBL3430520 | 0.79 | NR4A2 (0.62) | NR4A2KCNH2CYP11B1CYP11B2ALDH1A3 | |
| SCHEMBL3431737 | 0.79 | NR4A2 (0.75) | NR4A2KCNH2CYP11B1CYP11B2ALDH1A3 | |
| SCHEMBL3429756 | 0.77 | NR4A2 (0.69) | NR4A2KCNH2CYP11B1CYP11B2ALDH1A3 | |
| SCHEMBL1472110 | 0.76 | NR4A2 (1.00) | NR4A2KCNH2CYP11B1CYP11B2ALDH1A3 | |
| SCHEMBL3429517 | 0.76 | NR4A2 (0.68) | NR4A2KCNH2CYP11B1CYP11B2ALDH1A3 | |
| SCHEMBL3432610 | 0.76 | NR4A2 (0.67) | NR4A2KCNH2CYP11B1CYP11B2ALDH1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262805-B1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-10-22 | — | — | EP | claimed |
| US-8338451-B2 | Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI (FR) | 2012-12-25 | — | — | US | claimed |
| US-20110065727-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | claimed |
| EP-2262805-B1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-10-22 | — | — | EP | disclosed |
| US-20130123288-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (US) | 2013-05-16 | — | — | US | disclosed |
| US-8338451-B2 | Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI (FR) | 2012-12-25 | — | — | US | disclosed |
| US-20110065727-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | disclosed |
| EP-2262805-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009144395-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123288-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | ABL1, JAK2, REN | NR4A2 1640/4885KCNH2 1938/4885CYP11B1 18/4885 |
| US-20110065727-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | ABL1, JAK2, REN | NR4A2 1640/4885KCNH2 1938/4885CYP11B1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.